Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.66 |
| ▸ | NT5E | P21589 | 1/20 | 0.66 |
| ▸ | GSK3A | P49840 | 2/20 | 0.62 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.62 |
| ▸ | PNP | P00491 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.62 |
| ▸ | TGM2 | P21980 | 1/20 | 0.61 |
| ▸ | KRAS | P01116 | 6/20 | 0.59 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599196 | 0.96 | HINT1 (0.68) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL18520136 | 0.87 | HINT1 (0.69) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL3514472 | 0.86 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL3970953 | 0.86 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL17355882 | 0.86 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL27575151 | 0.86 | HINT1 (0.74) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL2014087 | 0.85 | HINT1 (0.72) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL11965261 | 0.85 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL116165 | 0.85 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL7111080 | 0.85 | HINT1 (0.72) | HINT1NT5EGSK3ARPS6KA3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6432966-B1 | — | — | None | — | — | US | disclosed |
| CN-113960201-A | Method for detecting 4-dimethylaminopyridine in entecavir | 山东鲁抗医药股份有限公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-213762193-U | Entecavir preparation is with high-efficient jet milling equipment | 山东海雅医药科技有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-112007040-A | Combined medicine for treating viral hepatitis B | 苏州瑞博生物技术股份有限公司 | 2020-12-01 | — | — | CN | disclosed |
| CN-107764891-B | Method for distinguishing and measuring entecavir chiral isomers | 杭州先导医药科技有限责任公司 | 2020-03-13 | — | — | CN | disclosed |
| EP-2536724-B2 | PROCESS FOR PREPARING ENTECAVIR AND ITS INTERMEDIATES | SCINOPHARM TAIWAN LTD (TW) | 2019-10-23 | — | — | EP | disclosed |
| US-20180044735-A1 | METHOD OF TREATING HEPATITIS B | ACADEMISCH MEDISCH CENTRUM (NL) | 2018-02-15 | — | — | US | disclosed |
| EP-2828401-B1 | MEANS AND METHODS FOR RESPONSE PREDICTION OF HEPATITIS B TREATMENT | ACAD MEDISCH CT (NL) | 2017-10-25 | — | — | EP | disclosed |
| EP-2536724-B1 | PROCESS FOR PREPARING ENTECAVIR AND ITS INTERMEDIATES | SCINOPHARM TAIWAN LTD (TW) | 2016-11-23 | — | — | EP | disclosed |
| US-20150044167-A1 | Means and Method for Response Prediction of Hepatitis B Treatment | ACADEMISCH MEDISCH CENTRUM (NL) | 2015-02-12 | — | — | US | disclosed |
| WO-2011102806-A1 | PROCESS FOR PREPARING ENTECAVIR AND ITS INTERMEDIATES | SCINOPHARM TAIWAN LTD (TW) | 2011-08-25 | — | — | WO | disclosed |
| US-20110201809-A1 | Process for Preparing Entecavir and its Intermediates | SCINOPHARM TAIWAN, LTD. | 2011-08-18 | — | — | US | disclosed |
| US-20080300222-A1 | Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization | INNATE PHARMA (FR) | 2008-12-04 | — | — | US | disclosed |
| EP-1933848-A2 | PHOSPHOANTIGEN SALTS OF ORGANIC BASES AND METHODS FOR THEIR CRYSTALLIZATION | Innate Pharma (FR) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039635-A2 | PHOSPHOANTIGEN SALTS OF ORGANIC BASES AND METHODS FOR THEIR CRYSTALLIZATION | INNATE PHARMA (FR) | 2007-04-12 | — | — | WO | disclosed |
| EP-1225904-B1 | COMBINATIONS OF LAMIVUDINE AND ENTECAVIR FOR TREATMENT OF HEPATITIS B VIRUS INFECTION | GLAXO GROUP LTD (GB) | 2004-08-11 | — | — | EP | disclosed |
| US-6432966-B2 | A SYNERGISTIC MIXTURE OF LAMIVUDINE AND BMS-200475 FOR THE TREATMENT OF A HEPITITIS B VIRAL INFECTION; EFFECTIVE AGAINST MUTANTS RESISTANT TO NUCLEOSIDE AND/OR NON-NUCLEOSIDE INHIBITORS OF THE REPLICATION OF THE HBV | SMITHKLINE BEECHAM CORPORATION | 2002-08-13 | — | — | US | disclosed |
| EP-1225904-A2 | COMBINATIONS OF LAMIVUDINE AND ENTECAVIR FOR TREATMENT OF HEPATITIS B VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2002-07-31 | — | — | EP | disclosed |
| US-20020002180-A1 | ANTIVIRAL COMBINATIONS | SMITHKLINE BEECHAM CORPORATION | 2002-01-03 | — | — | US | disclosed |
| WO-2001030329-A2 | COMBINATIONS OF LAMIVUDINE AND ENTECAVIR FOR TREATMENT OF HEPATITIS B VIRUS INFUCTION | GLAXO GROUP LIMITED (GB) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201809-A1 | Process for Preparing Entecavir and its Intermediates | ENTPD5, TYMS, TYMP | HINT1 647/4885NT5E 234/4885GSK3A 1718/4885 |
| US-20080300222-A1 | Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization | HLA-B, LCK, HLA-A | HINT1 2909/4885NT5E 2895/4885GSK3A 133/4885 |
| US-20020002180-A1 | ANTIVIRAL COMBINATIONS | HAVCR2, TYMP, ENTPD5 | HINT1 473/4885NT5E 86/4885GSK3A 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.